MedTrace Logo

Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)

NCT05745961 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2024-10-15

No results posted yet for this study

Summary

The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand \[11C\]PBR28) in the lungs of patients living with PAH relative to age matched controls. If so, TSPO PET may be a useful technique to non-invasively monitor response to therapy. To do this, we will perform 2 \[11C\]PBR28 PET scans. The first will quantify the total \[11C\]PBR28 PET signal. This signal is a combination of the specific signal (VS) and the nonspecific signal (VND). The second scan will be performed following dosing with an unlabelled TSPO ligand. By directly measuring the total \[11C\]PBR28 signal (scan 1) and the nonspecific \[11C\]PBR28 signal (scan 2) we can therefore calculate the specific \[11C\]PBR28 signal, and hence the amount of TSPO in the lung.

Conditions

Interventions

RADIATION

TSPO PET scan (11C-PBR28)

PET scan

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Martin Wilkins · Imperial College London

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-02-28
Completion
2025-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05745961 on ClinicalTrials.gov